Multiple Myeloma in 2023 Ways: From Trials to Real Life.

Autor: Fazio M; Post-Graduation School of Haematology, University of Catania, A.O.U. 'Policlinico-San Marco', 95123 Catania, Italy., Del Fabro V; Division of Haematology and BMT, A.O.U. 'Policlinico-San Marco', 95123 Catania, Italy., Parrinello NL; Division of Haematology and BMT, A.O.U. 'Policlinico-San Marco', 95123 Catania, Italy., Allegra A; Division of Haematology, Department of Human Pathology in Adulthood and Childhood 'Gaetano Barresi', University of Messina, 98125 Messina, Italy., Markovic U; Division of Haematology and BMT, A.O.U. 'Policlinico-San Marco', 95123 Catania, Italy., Botta C; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties 'G. D'Alessandro', University of Palermo, 90127 Palermo, Italy., Accardi F; Department of Hematology I, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy., Vincelli ID; Haematology Unit, Haemato-Oncology and Radiotherapy Department, Grande Ospedale Metropolitano 'Bianchi-Melacrino-Morelli', 89124 Reggio Calabria, Italy., Leotta S; Division of Haematology and BMT, A.O.U. 'Policlinico-San Marco', 95123 Catania, Italy., Elia F; Division of Haematology and BMT, A.O.U. 'Policlinico-San Marco', 95123 Catania, Italy., Esposito B; Post-Graduation School of Haematology, University of Catania, A.O.U. 'Policlinico-San Marco', 95123 Catania, Italy., Garibaldi B; Post-Graduation School of Haematology, University of Catania, A.O.U. 'Policlinico-San Marco', 95123 Catania, Italy., Sapuppo G; Post-Graduation School of Haematology, University of Catania, A.O.U. 'Policlinico-San Marco', 95123 Catania, Italy., Orofino A; Post-Graduation School of Haematology, University of Catania, A.O.U. 'Policlinico-San Marco', 95123 Catania, Italy., Romano A; Dipartimento di Specialità Medico-Chirurgiche, CHIRMED, Sezione di Ematologia, Università degli Studi di Catania, 95131 Catania, Italy., Palumbo GA; Dipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate 'G.F.Ingrassia', University of Catania, 95131 Catania, Italy., Di Raimondo F; Post-Graduation School of Haematology, University of Catania, A.O.U. 'Policlinico-San Marco', 95123 Catania, Italy.; Division of Haematology and BMT, A.O.U. 'Policlinico-San Marco', 95123 Catania, Italy.; Dipartimento di Specialità Medico-Chirurgiche, CHIRMED, Sezione di Ematologia, Università degli Studi di Catania, 95131 Catania, Italy., Conticello C; Division of Haematology and BMT, A.O.U. 'Policlinico-San Marco', 95123 Catania, Italy.
Jazyk: angličtina
Zdroj: Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Nov 03; Vol. 30 (11), pp. 9710-9733. Date of Electronic Publication: 2023 Nov 03.
DOI: 10.3390/curroncol30110705
Abstrakt: Multiple myeloma is a chronic hematologic malignancy that obstinately tends to relapse. Basic research has made giant strides in better characterizing the molecular mechanisms of the disease. The results have led to the manufacturing of new, revolutionary drugs which have been widely tested in clinical trials. These drugs have been approved and are now part of the therapeutic armamentarium. As a consequence, it is essential to combine what we know from clinical trials with real-world data in order to improve therapeutic strategies. Starting with this premise, our review aims to describe the currently employed regimens in multiple myeloma and compare clinical trials with real-life experiences. We also intend to put a spotlight on promising therapies such as T-cell engagers and chimeric antigen receptor T-cells (CAR-T) which are proving to be effective in changing the course of advanced-stage disease.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje